| 0078-0701 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0701-51 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0701-84 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0708 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0708-02 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0708-51 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0708-90 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0708-91 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0715 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0715-02 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0715-61 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0715-91 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-0715-94 | These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1021 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1021-51 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1021-84 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1021-90 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1021-91 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1028 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1028-51 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1028-84 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1028-90 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1028-91 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1035 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1035-02 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1035-61 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1035-92 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1035-94 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1133 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1140 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1175 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1175-19 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |
| 0078-1175-51 | These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019 | Novartis Pharmaceuticals Corporation |